ES2388993T3 - Procedimientos y composiciones para modular y detectar actividad de WISP - Google Patents

Procedimientos y composiciones para modular y detectar actividad de WISP Download PDF

Info

Publication number
ES2388993T3
ES2388993T3 ES06750127T ES06750127T ES2388993T3 ES 2388993 T3 ES2388993 T3 ES 2388993T3 ES 06750127 T ES06750127 T ES 06750127T ES 06750127 T ES06750127 T ES 06750127T ES 2388993 T3 ES2388993 T3 ES 2388993T3
Authority
ES
Spain
Prior art keywords
wisp
cells
antagonist
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06750127T
Other languages
English (en)
Spanish (es)
Inventor
Luc Desnoyers
Ellen Filvaroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2388993T3 publication Critical patent/ES2388993T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES06750127T 2005-04-14 2006-04-13 Procedimientos y composiciones para modular y detectar actividad de WISP Expired - Lifetime ES2388993T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US105876 2002-03-25
US11/105,876 US7455834B2 (en) 2002-06-29 2005-04-14 Methods and compositions for modulating and detecting WISP activity
PCT/US2006/014008 WO2006113402A1 (en) 2005-04-14 2006-04-13 Methods and compositions for modulating and detecting wisp activity

Publications (1)

Publication Number Publication Date
ES2388993T3 true ES2388993T3 (es) 2012-10-22

Family

ID=36809580

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06750127T Expired - Lifetime ES2388993T3 (es) 2005-04-14 2006-04-13 Procedimientos y composiciones para modular y detectar actividad de WISP

Country Status (16)

Country Link
US (2) US7455834B2 (cg-RX-API-DMAC7.html)
EP (1) EP1869086B1 (cg-RX-API-DMAC7.html)
JP (1) JP4979684B2 (cg-RX-API-DMAC7.html)
KR (1) KR101320261B1 (cg-RX-API-DMAC7.html)
CN (1) CN101198623B (cg-RX-API-DMAC7.html)
AU (1) AU2006236649B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612184A8 (cg-RX-API-DMAC7.html)
CA (1) CA2604933C (cg-RX-API-DMAC7.html)
ES (1) ES2388993T3 (cg-RX-API-DMAC7.html)
IL (1) IL186095A (cg-RX-API-DMAC7.html)
MX (1) MX2007012798A (cg-RX-API-DMAC7.html)
NO (1) NO20075825L (cg-RX-API-DMAC7.html)
NZ (1) NZ561709A (cg-RX-API-DMAC7.html)
RU (1) RU2412201C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006113402A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200708738B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455834B2 (en) * 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
KR20150134346A (ko) * 2013-03-27 2015-12-01 지이 헬스케어 에이에스 진단 조성물을 제조하기 위한 방법 및 시약
CN106456732A (zh) * 2014-04-15 2017-02-22 索伦托治疗有限公司 结合wisp1的抗体疗法
KR102011366B1 (ko) * 2016-11-17 2019-10-14 연세대학교 산학협력단 암 전이 억제제의 스크리닝 방법
EP4365299A3 (en) * 2018-05-17 2024-08-07 Olives Biotherapeutics Inc. Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
PT1623990E (pt) 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
JP4636497B2 (ja) 2002-06-29 2011-02-23 ジェネンテック, インコーポレイテッド Wisp活性を調節し検出するための方法及び組成物
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
JP2007505131A (ja) 2003-09-11 2007-03-08 ジェネンテック・インコーポレーテッド Wispアンタゴニストの使用方法

Also Published As

Publication number Publication date
CN101198623A (zh) 2008-06-11
IL186095A (en) 2012-10-31
CA2604933C (en) 2014-07-08
CN101198623B (zh) 2013-06-12
AU2006236649A2 (en) 2008-07-24
IL186095A0 (en) 2008-01-20
ZA200708738B (en) 2009-01-28
BRPI0612184A8 (pt) 2017-12-26
US7732567B2 (en) 2010-06-08
NZ561709A (en) 2009-12-24
AU2006236649A1 (en) 2006-10-26
CA2604933A1 (en) 2006-10-26
AU2006236649B2 (en) 2012-03-29
JP2008537958A (ja) 2008-10-02
MX2007012798A (es) 2007-11-20
KR101320261B1 (ko) 2013-10-22
HK1112470A1 (en) 2008-09-05
EP1869086A1 (en) 2007-12-26
US20060147453A1 (en) 2006-07-06
RU2007142005A (ru) 2009-05-20
KR20080003344A (ko) 2008-01-07
RU2412201C2 (ru) 2011-02-20
JP4979684B2 (ja) 2012-07-18
EP1869086B1 (en) 2012-07-18
WO2006113402A1 (en) 2006-10-26
BRPI0612184A2 (pt) 2011-12-20
NO20075825L (no) 2008-01-11
US20090148448A1 (en) 2009-06-11
US7455834B2 (en) 2008-11-25

Similar Documents

Publication Publication Date Title
ES2325305T3 (es) Anticuerpos dr4 quimericos y usos de los mismos.
US20050070689A1 (en) Taci and br3 polypeptides and uses thereof
RU2365382C2 (ru) Композиции и способы для регуляции развития сосудов
US7732567B2 (en) Methods and compositions for modulating and detecting wisp activity
BG65473B1 (bg) Използване на april рецепторни антагонисти
US20040120947A1 (en) DR4 antibodies and uses thereof
JP4636497B2 (ja) Wisp活性を調節し検出するための方法及び組成物
ES2349162T3 (es) Procedimientos y composiciones para modular y detectar la actividad de wisp.
JP2007505131A (ja) Wispアンタゴニストの使用方法
HK1112470B (en) Methods and compositions for modulating and detecting wisp activity